Mercury Laboratories [MERCURYLAB] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison

Mercury Laboratories

BSE
Loading...

Aarti Drugs

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Mercury Laboratories wins in 10 metrics, Aarti Drugs wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

MetricMercury LaboratoriesAarti DrugsBetter
P/E Ratio (TTM)26.0923.66Aarti Drugs
Price-to-Book Ratio1.843.26Mercury Laboratories
Debt-to-Equity Ratio10.1844.92Mercury Laboratories
PEG Ratio0.140.37Mercury Laboratories
EV/EBITDA13.9017.07Mercury Laboratories
Profit Margin (TTM)4.93%7.80%Aarti Drugs
Operating Margin (TTM)8.34%10.11%Aarti Drugs
EBITDA Margin (TTM)8.34%10.11%Aarti Drugs
Return on Equity5.87%12.28%Aarti Drugs
Return on Assets (TTM)4.23%6.53%Aarti Drugs
Free Cash Flow (TTM)$-50.39M$674.22MAarti Drugs
Dividend Yield0.82%0.22%Mercury Laboratories
1-Year Return-17.07%-4.79%Aarti Drugs
Price-to-Sales Ratio (TTM)1.291.84Mercury Laboratories
Enterprise Value$1.02B$50.47BAarti Drugs
EV/Revenue Ratio1.342.08Mercury Laboratories
Gross Profit Margin (TTM)60.02%36.77%Mercury Laboratories
Revenue per Share (TTM)$638$265Mercury Laboratories
Earnings per Share (Diluted)$31.43$20.63Mercury Laboratories
Beta (Stock Volatility)0.570.12Aarti Drugs
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Mercury Laboratories vs Aarti Drugs Stock Performance Analysis

Loading Price Chart...

Mercury Laboratories
Aarti Drugs
Mercury Laboratories Stock Overview | Aarti Drugs Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Mercury Laboratories3.66%3.84%1.80%-0.74%1.18%-4.50%
Aarti Drugs0.73%4.61%0.24%1.59%41.06%7.93%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Mercury Laboratories-17.07%42.15%92.55%110.81%2,274.30%2,274.30%
Aarti Drugs-4.79%-0.89%-50.06%219.30%2,690.01%2,872.19%

News Based Sentiment: Mercury Laboratories vs Aarti Drugs

Mercury Laboratories

News based Sentiment: MIXED

September presented a mixed bag for Mercury Laboratories, with a positive valuation upgrade countered by concerns over profitability and a declining share price over the past year. The volatility and conflicting signals make it a significant month for investors to assess the company's direction.

View Mercury Laboratories News Sentiment Analysis

Aarti Drugs

News based Sentiment: POSITIVE

Aarti Drugs reported substantial profit growth in both Q1FY26 and FY2025, coupled with increased institutional interest from Mutual Funds. While shareholding changes and recent price volatility exist, the overall narrative points towards a strengthening investment case.

View Aarti Drugs News Sentiment Analysis

Performance & Financial Health Analysis: Mercury Laboratories vs Aarti Drugs

MetricMERCURYLABAARTIDRUGS
Market Information
Market Cap i₹1.02B₹44.55B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i28201,942
90 Day Avg. Volume i138187,563
Last Close₹850.00₹491.60
52 Week Range₹736.00 - ₹1,190.00₹312.00 - ₹564.05
% from 52W High-28.57%-12.84%
All-Time High₹1,303.00 (Jan 08, 2024)₹1,026.95 (Oct 05, 2020)
% from All-Time High-34.77%-52.13%
Growth Metrics
Quarterly Revenue Growth0.09%0.06%
Quarterly Earnings Growth1.83%0.62%
Financial Health
Profit Margin (TTM) i0.05%0.08%
Operating Margin (TTM) i0.08%0.10%
Return on Equity (TTM) i0.06%0.12%
Debt to Equity (MRQ) i10.1844.92
Cash & Liquidity
Book Value per Share (MRQ)₹446.41₹149.84
Cash per Share (MRQ)₹12.97₹2.48
Operating Cash Flow (TTM) i₹-12,625,000₹2.83B
Levered Free Cash Flow (TTM) i₹31.45M₹1.68B
Dividends
Last 12-Month Dividend Yield i0.82%0.22%
Last 12-Month Dividend i₹7.00₹1.00

Valuation & Enterprise Metrics Analysis: Mercury Laboratories vs Aarti Drugs

MetricMERCURYLABAARTIDRUGS
Price Ratios
P/E Ratio (TTM) i26.0923.66
Forward P/E iN/A15.02
PEG Ratio i0.140.37
Price to Sales (TTM) i1.291.84
Price to Book (MRQ) i1.843.26
Market Capitalization
Market Capitalization i₹1.02B₹44.55B
Enterprise Value i₹1.02B₹50.47B
Enterprise Value Metrics
Enterprise to Revenue i1.342.08
Enterprise to EBITDA i13.9017.07
Risk & Other Metrics
Beta i0.570.12
Book Value per Share (MRQ) i₹446.41₹149.84

Financial Statements Comparison: Mercury Laboratories vs Aarti Drugs

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)MERCURYLABAARTIDRUGS
Revenue/Sales i₹181.35M₹5.91B
Cost of Goods Sold i₹72.50M₹3.73B
Gross Profit i₹108.85M₹2.17B
Research & Development iN/AN/A
Operating Income (EBIT) i₹15.12M₹593.60M
EBITDA i₹25.36M₹743.90M
Pre-Tax Income i₹15.47M₹511.10M
Income Tax i₹5.80M₹-28.60M
Net Income (Profit) i₹9.68M₹539.70M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)MERCURYLABAARTIDRUGS
Cash & Equivalents i₹3.32M₹45.77M
Total Current Assets i₹401.60M₹13.38B
Total Current Liabilities i₹150.76M₹8.37B
Long-Term Debt i₹37.83M₹2.86B
Total Shareholders Equity i₹535.69M₹13.69B
Retained Earnings i₹86.56M₹12.40B
Property, Plant & Equipment i₹85.40M₹27.03M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)MERCURYLABAARTIDRUGS
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricMERCURYLABAARTIDRUGS
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i28201,942
Average Daily Volume (90 Day) i138187,563
Shares Outstanding i1.20M91.27M
Float Shares i166,41639.04M
% Held by Insiders i0.86%0.60%
% Held by Institutions i0.00%0.11%

Dividend Analysis & Yield Comparison: Mercury Laboratories vs Aarti Drugs

MetricMERCURYLABAARTIDRUGS
Last 12-Month Dividend i₹7.00₹1.00
Last 12-Month Dividend Yield i0.82%0.22%
3-Year Avg Annual Dividend i₹4.67₹1.00
3-Year Avg Dividend Yield i0.43%0.23%
3-Year Total Dividends i₹14.00₹3.00
Ex-Dividend DateAug 06, 2025Feb 04, 2025